Bresat Cancer Update
Oncology Leader CommentarySpecial FeaturesPrevious Issues

Home: Oncology Leader Commentary: Nancy E. Davidson, MD

Click on the topic below for comments by Dr Nancy E. Davidson to comment on. You will also find links to related articles and clinical trials.

Intergroup study of adjuvant ovarian suppression
Main results of Intergroup adjuvant premenopausal study
Management of node-postive, ER+ premenopausal patients
Ovarian ablation after chemotherapy in patients who continue to menstrate
Harvey study of estrogen receptors
Use of adjuvant tamoxifen
Choice of aromatase inhibitor
Management of metastatic disease in younger women
Combined endocrine therapy in premenopausal patients with metastases
Tamoxifen for patients with DCIS
Psychosocial issue in young breast cancer patients
Risk for recurrence and use of cytotoxic therapy
Use of prognostic factors in invasive breast cancer

Management of node-postive, ER+ premenopausal patients

Interview with Neil Love, MD from Breast Cancer Update for Medical Oncologists, Program 3 2000

Play Audio Below:

I think most everybody in this country, in the United States, would agree that those women are candidates for chemotherapy. Most of them would get tamoxifen as a matter of routine. And I think the big question for a lot practitioners in our country is what do you do with the young woman who is premenopausal at the end of her chemotherapy? I personally am not using LHRH agonists in this situation right now, but I must say some of our very good colleagues have looked at my trial results and sort of put it in the context and said that they think it’s a legitimate thing to do. A little bit in this country, and I think more abroad, is actually the question of whether or not you need to do the chemo at all. I mean, these particular women given the fact that there are several international trials that would suggest – I’m not sure the statisticians would allow us to say it - but there’s the sense that there might be equivalence between various chemotherapies, usually CMF based chemotherapies, and some kind of LHRH agonist with or without tamoxifen. I think folks are also starting to challenge the question of whether you absolutely have to give chemotherapy to these women. It’s going to be tough in the U.S. to overcome our bias towards chemotherapy.

Relevant Links:

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study.
Klijn, J. G. M.; Beex LVAM; Mauriac, L.; van Zijl, J. A.; Veyret, C.; Wildiers, J.; Jassem, J. Piccart, M.; Burghouts, J.; Becquart, D.; Seynaeve, C.; Mignolet, F., and Duchateau, L. (Reprint available from: Klijn JGM Dr Daniel den Hoed Klin, Rotterdam Canc Inst, Dept Med Oncol Groene Hilledijk 301 NL-3075 EA Rotterdam Netherlands). Journal of the National Cancer Institute. 92(11):903-911, 2000 Jun 7.

Prevention of rat mammary carcinoma utilizing leuprolide as an equivalent to oophorectomy.
Jett, E. A.; Lerner, M. R.; Lightfoot, S. A.; Hanas, J. S.; Brackett, D. J., and Hollingsworth, A. B. (Reprint available from: Hollingsworth AB Mercy Hosp, Womens Ctr 4300 McAuley Blvd Oklahoma City, OK 73120 USA). Breast Cancer Research & Treatment. 58(2):131-136, 1999 Nov.

Combined endocrine therapy for breast cancer - New life for an old idea?
Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No abstract

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial.
Boccardo, F.; Rubagotti, A.; Amoroso, D.; Mesiti, M.; Romeo, D.; Sismondi, P.; Giai, M.; Genta, F.; Pacini, P.; Distante, V.; Bolognesi, A.; Aldrighetii, D., and Farris, A.. Journal of Clinical Oncology. 18(14):2718-2727, 2000 Jul. http://www.jco.org/cgi/content/abstract/

Age-related variation in the treatment and outcomes of patients with breast carcinoma
Golledge, J.; Wiggins, J. E., and Callam, M. J.. Cancer. 88(2):369-374, 2000 Jan 15.

Quality of life after adjuvant chemotherapy for breast cancer.
Broeckel, J. A.; Jacobsen, P. B.; Balducci, L.; Horton, J., and Lyman, G. H. Breast Cancer Research & Treatment. 62(2):141-150, 2000 Jul.

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer.
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

Aebi, S.; Gelber, S.; Castiglione-Gertsch, M.; Gelber, R. D.; Collins, J.; Thurlimann, B.; Rudenstam, C. M.; Lindtner, J.; Crivellari, D.; Cortes-Funes, H.; Simoncini, E.; Werner, I. D.; Coates, A. S., and Goldhirsch, A. Lancet. 355(9218):1869-1874, 2000 May 27.

Bos, A. M. E.; de Graaf, H.; de Vries, E. G. E.; Piersma, H., and Willemse, P. H. B. (Reprint available from: Bos AME Univ Groningen Hosp, Div Med Oncol, Dept Internal Med POB 30 001 NL-9700 RB Groningen Netherlands).. British Journal of Cancer. 82(12):1920-1924, 2000 June

Study of Tamoxifen in the Prevention of Skeletal and Cardiovascular Morbidity of Adjuvant Chemotherapy in Premenopausal Women With Stage I or II Breast Cancer

Relevant Clinical Trials:

Phase II Study of Exemestane and Goserelin in Premenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Top of Page

Home · Contact us
Terms of use and general disclaimer